TY - JOUR T1 - FDG PET-CT in Immunotherapy JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 2047 LP - 2047 VL - 62 IS - supplement 1 AU - Yamil Fourzali AU - Saima Muzahir Y1 - 2021/05/01 UR - http://jnm.snmjournals.org/content/62/supplement_1/2047.abstract N2 - 2047Objectives: Pictorial review of FDG PET/CT in Immunotherapy, with the description of the different available treatments and their effects, including immune related adverse events, seen on PET/CT, as well as the comparison of the different proposed response criteria methods used with anatomic imaging and/or PET/CT. Methods and Results: Definition of Immunotherapy and dysregulation of tumor cells. Description of the different immunotherapies currently available in Oncology, which include Monoclonal Antibodies, Vaccines, Oncolytic Virus Therapy, Adoptive Cell Therapy and Immune Checkpoint inhibitors (iCPI). iCPI, are described in more detail, including important terms like pseudoprogression, hyperprogression, Abscopal effect and immune-related adverse events (iAE), with respective FDG PET/CT examples. Will also describe the different methods proposed for response criteria, from the most commonly used in clinical trials iRECIST, to the newer ones like PECRIT, PERCIMT, imPERCIST5 and LYRIC for lymphoma. Examples of iAE will also be presented. Will also explain the importance of dendritic cells and T cells in the immune respone to cancer cells, as well as understanding newer concepts like iUPD, iCPD, clinical benefit and indeterminate response. Conclusions: Immunotherapy has been introduced as a new paradigm in cancer treatment with new challenges when evaluating response criteria and side effects. The better we understand basic concepts associated with all of these different treatments, including new proposed methods for assessing response and their side effects, the better we will be able to help our oncologic patients treated with immunotherapy. ER -